TY - JOUR
T1 - Rash from EGFR inhibitors
T2 - Opportunities and challenges for palliation
AU - Solomon, Benjamin M.
AU - Jatoi, Aminah
PY - 2008
Y1 - 2008
N2 - The epidermal growth factor receptor (EGFR) inhibitors represent a relatively new class of cancer agents that also provide new challenging side effects for cancer patients. This article reviews the clinical aspects of EGFR inhibitor-induced rash, which occurs most commonly with use of these agents, and discusses some of the challenges faced in attempting palliation treatment.
AB - The epidermal growth factor receptor (EGFR) inhibitors represent a relatively new class of cancer agents that also provide new challenging side effects for cancer patients. This article reviews the clinical aspects of EGFR inhibitor-induced rash, which occurs most commonly with use of these agents, and discusses some of the challenges faced in attempting palliation treatment.
UR - http://www.scopus.com/inward/record.url?scp=56149086186&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=56149086186&partnerID=8YFLogxK
U2 - 10.1007/s11912-008-0048-1
DO - 10.1007/s11912-008-0048-1
M3 - Review article
C2 - 18778556
AN - SCOPUS:56149086186
SN - 1523-3790
VL - 10
SP - 304
EP - 308
JO - Current oncology reports
JF - Current oncology reports
IS - 4
ER -